Search PubMed⌕ Search

Biomedical subjects

J Harvey

Publications and source records attributed to J Harvey.

304 records · Page 17Linked to original sources
PubMedDate not supplied

Women's experience of early miscarriage: a phenomenological study.

This paper describes the experience of three women who had experienced early miscarriage within the previous 12 months. Three major themes of loss emerged: the loss of a baby, the loss of the role of motherhood and the loss of the hopes and dreams the women possessed for their baby. These losses were complicated by the women's negative thoughts about the care they received while in hospital, their perceptions of health professional's negative attitudes, the lack of information given to them, and the lack of understanding shown by family and friends about their situation. The authors recommend a number of changes to practice including the need for an increased sensitivity towards women following early miscarriage.

Abortion, Spontaneous↗
PubMedDate not supplied

Case management in Australia: application of Moxley's scenarios.

In 1989 David Moxley produced a text for generic case management in the human services. He has revisited his initial work and argues that the case management concept has taken on diverse meaning as it has been applied more widely and for very different agendas. It may have emerged in community care, but is now being utilised as a tool of restructuring in all arenas of service provision. Moxley now suggests five distinct scenarios for the future of case management: community support and the organisation of support systems for people with disabilities; management of the economic costs of human services; the management of undesirables; the management of clinical pathways; recipient management services. His commentary is based on his U.S. experience. This article will examine the relevance of his predictions to the Australian context.

Australia↗
PubMedDate not supplied

Chronosynergistic effects of lighting schedule-shift and cefodizime on plasmacytoma growth and host survival time.

Lighting regimen shifts can modify the effects of cefodizime, for the purpose of a chronoimmunomodulation. Two experiments were carried out on male and female LOU rats inoculated subcutaneously with plasmacytoma cells. Some rats were kept on their original LD12:12 regimen, whereas others, after tumor implantation, were subjected every second day to 6-h shifts, instituted, in alternation, as advance or delay. Daily treatment with cefodizime or placebo started when, overall, about 50% of the animals had developed a palpable tumor. A subgroup of animals contributed daily smears for the determination of the estrus cycle and further provided core temperature and activity data by telemetry. In Experiment I, the repeated shifting of the LD regimen was associated with survival time prolongation (p less than 0.05), irrespective of drug administration. Moreover, in those (female) rats repeatedly exposed to shifts of the lighting schedule, cefodizime was found to prolong survival time (p less than 0.05). The effects of cefodizime vs placebo on survival time were found to be circadian stage-dependent. In Experiment II, differing from Experiment I in the initial conditions before the institution of the shifts, cefodizime treatment was associated with a prolongation of survival time of the female rats kept on a fixed LD12:12 regimen. Both male and female rats again showed a circadian stage-dependence of the cefodizime effect. These results suggest that interactions between synchronizers of rhythms (such as shifts of the lighting regimen, the latter simulating the daily routine) and immunomodulating agents such as cefodizime may be optimized to improve treatment strategies against cancer and other diseases.

Animals↗
PubMedDate not supplied

Intermittent automatic chronobiologic monitoring complements daily self-measurements.

The self-measurement of blood pressure for circadian rhythm assessment has been used for the evaluation, 'as one goes', of the effectiveness of treatment for high blood pressure (among other purposes). Even in a setting of high technology, with miniaturized ambulatory fully automatic recorders available, it is cost-effective to combine self- with automatic blood pressure measurement, to check on both the adequacy of treatment and the need for it. These aims were followed by an 81-year-old physician practicing autorhythmometry for over a decade.

Aged↗
PubMedDate not supplied

Heterogeneity of HLA-DR4 in the rheumatoid arthritis of a Chippewa band.

A high frequency of both rheumatoid arthritis (RA) and HLA-DR4 was found in a Chippewa Indian population. Multiple immunogenetic "variants" of HLA-DR4 were demonstrated, each showing a different response in mixed lymphocyte culture which corresponded to a serologic pattern of reactivity to a panel of non-DR4 B cell alloantisera. No DR4-bearing HLA haplotype or DR4 "variant" was common to subjects with RA, all of whom were DR4-positive. The implications are discussed.

Arthritis, Rheumatoid↗
PubMedDate not supplied

Cathepsin-D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics.

The relationship between the Cathepsin-D concentration in breast cancer cytosols and clinical and histopathological characteristics of the tumours was investigated, including vascular invasion, histological type, histological grade, lymph node involvement and tumour size. The median cathepsin-D concentration of a series of 738 primary breast carcinomas was used to define "low" and "high" cathepsin-D. High cathepsin-D concentration was associated with peritumoral vascular invasion, with high grade infiltrating duct carcinomas, with tumours of > or = 2 diameter, and with metastases in the axillary lymph nodes. Low cathepsin-D concentration was associated with in-situ carcinomas.

Breast Neoplasms↗
PubMedDate not supplied

Hypermethylation of the myogenic gene Myf-3 in human breast carcinomas.

The methylation status of Myf-3 was studied in 34 human primary breast carcinomas and 9 normal breast tissues. One third of the carcinomas contained hypermethylated Myf-3. All normal tissues contained unmethylated Myf-3. Myf-3 hypermethylation was more common in poorly differentiated grade 3 tumours than in better differentiated grade 1 and 2 tumours.

Adenocarcinoma↗
PubMedDate not supplied

Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up.

Amplification of erbB-1 and c-erbB-2 genes has been shown in human breast cancer. Expression of these protooncogenes results in production of epidermal growth factor receptor (EGFR) and c-erbB-2. Both are transmembrane receptors with tyrosine kinase activity. Recent data have indicated that the external domain of c-erbB-2 is shed into the culture supernatant of certain breast cancer cell lines and sera of breast cancer patients. A body of literature has shown that the overexpression of these receptors in malignant tissue and c-erbB-2 when shed into serum is associated with bad prognosis. In the present work, tissue EGFR and c-erbB-2 were determined in the membrane fractions of histopathologically verified malignant and normal tissues from the same breast of 94 patients. These values were also determined in 48 tissue specimens of benign mastopathies. Serum c-erbB-2 was quantified in breast cancer patients (n = 105), patients with benign breast disease (n = 48) and 30 apparently healthy women as controls. Patients were followed up by determination of serum c-erbB-2 for one year and clinically for three years to detect any distant metastasis or recurrence. The levels of tissue and serum c-erbB-2 and Estrogen receptors were significantly higher in the carcinomas and sera of breast cancer patients than benign breast diseases or normal controls. Follow-up, although short, of pre-operative serum c-erbB-2 showed a prognostic value (P = 0.007) better than that of tumor size (P = 0.04), EGFR (P = 0.18), nodal involvement (P = 0.25) and tissue c-erbB-2 (P = 0.85). The shedding of soluble fragments of c-erbB-2 into the serum seems to be a characteristic of the potentially malignant cell. The EGFR mean level, however, was significantly lower in malignant tissues than benign and normal ones. A new definition of EGFR status was developed. Accordingly, the recurrence of the disease was more frequent among patients with negative EGFR. The present work did not reveal any correlation between tissue, serum c-erbB-2 or EGFR on one hand and age, menopausal status, stage, histological type and grade of carcinomas and nodal involvement on the other hand. The present work showed an inverse correlation between estrogen receptor level and level of EGFR in malignant tissues.

Adult↗
PubMedDate not supplied

Epidermal growth factor receptors: status and effect on breast cancer patients.

The predictive potential of Epidermal Growth Factor Receptor (EGFR) is still a matter of debate. EGFR was quantified biochemically using an enzyme immunoassays malignant and normal tissues from the same breast (n = 94) as well as benign mastopathies (n = 40). The mean level of EGFR in malignant tissues showed a significant decrease from the control and benign ones with a weak positive correlation existing between EGFR level in malignant and control tissue of the same breast. Statistically, no cut-off line could be drawn between malignant and non malignant tumors due to the large overlap in their values. On the contrary to reports on EGFR, when the patients were classified according to the relative changes in EGFR from malignant and adjacent tissue, patients with a relative EGFR decrease (negative EGFR) in malignant tissue showed the poorer prognosis in short term follow up. Mean EGFR values in malignant or normal tissue, or the difference between them, did not show any significant correlation with the age of the patients, menstrual status, clinical stage, type and grade of the carcinoma and lymph node involvement. The present work showed also an inverse correlation between EGFR and Estrogen Receptor (ER) level in the malignant tissues.

Adult↗